Načítá se...
Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
It is strongly suggested that dipeptidyl peptidase‐4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor use is required in daily diabetes care.[Ima...
Uloženo v:
| Vydáno v: | J Diabetes Investig |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717917/ https://ncbi.nlm.nih.gov/pubmed/30989811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13060 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|